Frequency and Severity of Comorbid Mood and Anxiety Disorders in Prescription Opioid Dependence
Article first published online: 25 APR 2013
Copyright © American Academy of Addiction Psychiatry
The American Journal on Addictions
Volume 22, Issue 3, pages 261–265, May-June 2013
How to Cite
Gros, D. F., Milanak, M. E., Brady, K. T. and Back, S. E. (2013), Frequency and Severity of Comorbid Mood and Anxiety Disorders in Prescription Opioid Dependence. The American Journal on Addictions, 22: 261–265. doi: 10.1111/j.1521-0391.2012.12008.x
- Issue published online: 25 APR 2013
- Article first published online: 25 APR 2013
- Manuscript Accepted: 6 AUG 2012
- Manuscript Revised: 26 JUN 2012
- Manuscript Received: 27 MAR 2012
Background and Objectives
Comorbid substance use disorders and mood and anxiety disorders are associated with more severe psychiatric symptoms, social and occupational impairment, and economic burden. To date, the majority of research has focused on comorbidity in illicit drug users, rather than prescription drug users. To address this gap in the literature, the present cross-sectional study investigated the clinical profiles of individuals with prescription opioid dependence with or without comorbid mood and anxiety disorders.
Ninety individuals with prescription opioid use were recruited to participate in the study procedures. All participants completed a structured clinical interview and series of self-report measures.
Results and Conclusions
Of the 85 individuals with prescription opioid dependence, 47.1% (n = 40) were diagnosed with a comorbid mood or anxiety disorder. The findings showed that individuals with prescription opioid dependence and comorbid mood and anxiety disorders demonstrated significantly more severe alcohol use, psychiatric symptoms, and sleep impairment than individuals without comorbidity.
The findings highlight the frequency and severity of co-occurring mood and anxiety disorders in individuals with prescription opioid dependence and suggest that integrated interventions are needed to address these growing problems. (Am J Addict 2013; 22:261–265)